TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA expanded approval of mavacamten (Camzyos) to children weighing at least 30 kg who have symptomatic obstructive hypertrophic cardiomyopathy. The decision was based on a 44-adolescent trial showing reduced obstruction over 28 weeks; treatment carries heart-function risks and requires participation in a restricted safety program.
The U.S. Food and Drug Administration expanded approval of mavacamten (Camzyos) to children weighing at least 30 kilograms (about 66 pounds) who have symptomatic obstructive hypertrophic cardiomyopathy (HCM). The decision gives eligible pediatric patients an FDA-approved drug in the cardiac myosin inhibitor class, while requiring careful monitoring because the medicine can impair heart function.
The expanded indication covers children with symptomatic obstructive HCM and a body weight of at least 30 kg. The drug is intended to improve symptoms and functional capacity. Mavacamten was first approved for adults with obstructive HCM in 2022; the FDA action now extends its use to a younger group. MedPage Today described it as the first cardiac myosin inhibitor approved for pediatric patients with the condition.
The pediatric approval was based on the phase III SCOUT-HCM randomized trial, which enrolled 44 adolescents. Participants had specified measures of left ventricular function and outflow obstruction and were receiving background treatment with a beta blocker, calcium channel blocker and/or disopyramide. At week 28, the mavacamten group had a reported 48.0 mm Hg reduction from baseline in the Valsalva left ventricular outflow tract (LVOT) gradient compared with placebo (P<0.0001).
Researchers also reported improvements in measures including obstruction at rest, diastolic function, cardiac hypertrophy and markers of cardiac stress and injury. The trial report, as summarized by MedPage Today, found no ejection-fraction readings below 50% among treated adolescents and no cases of atrial fibrillation, symptomatic heart failure or death. Those findings describe the study group and period; they do not establish that such risks are absent in broader or longer-term use.
A New Approved Option for Young Patients
The approval addresses a gap for some children with obstructive HCM, a condition that can restrict blood flow from the heart and cause symptoms. Pediatric drug treatment options have historically been limited, and this authorization gives clinicians a specifically approved therapy for eligible children rather than relying only on medicines not approved for this age group or condition.
The trial’s reduction in LVOT gradient is a measured change in obstruction, while the FDA indication also names improvement in symptoms and functional capacity as treatment goals. How much an individual child will benefit depends on clinical circumstances; the reported trial results do not show that every patient will respond in the same way or that the drug changes the long-term course of HCM.
Access also comes with safeguards. Mavacamten is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program because it can cause heart failure through systolic dysfunction. The expansion therefore matters both as a treatment option and as a decision requiring clinician oversight, heart-function monitoring and review of other medicines.
As an affiliate, we earn on qualifying purchases.
From Adult Approval to Pediatric Use
HCM involves thickening of the heart’s left ventricle without another cardiac, systemic or metabolic cause. The pediatric form is described in the source report as rare and often genetically inherited. In obstructive HCM, the thickened heart muscle can narrow the path through which blood leaves the left ventricle.
Mavacamten is a cardiac myosin inhibitor. Its adult approval in 2022 preceded the pediatric evidence from SCOUT-HCM. In March, investigator Joseph Rossano suggested that this drug class could eventually affect the natural history of pediatric obstructive HCM. That was a forward-looking view, not a finding established by the 28-week trial. Another medicine in the class, aficamten (Myqorzo), remains indicated for adults only, according to the report.
“For the first time, children with this serious condition have a therapy that is FDA-approved to reduce [LVOT] obstruction.”
— Joseph Rossano, MD, SCOUT-HCM investigator at Children’s Hospital of Philadelphia, in a Bristol Myers Squibb press release
As an affiliate, we earn on qualifying purchases.
Long-Term Effects Remain Unsettled
The available account does not specify the full prescribing details, monitoring schedule or the FDA’s complete label language for pediatric patients. It also does not establish long-term safety or effectiveness beyond the trial period, which assessed outcomes through 28 weeks. The absence of certain safety events among 44 adolescents in that study should not be read as proof that the risks cannot occur.
The source does not provide the magnitude of change for every secondary measure or say how the results translate into day-to-day outcomes for children. It remains unclear whether treatment can alter the longer-term progression of pediatric HCM; the possibility raised by the investigator is not a confirmed clinical outcome. Decisions about an individual patient’s suitability also depend on the full FDA label and clinical assessment.
blood pressure monitor for children
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Prescribing Under Safety Controls
Eligible patients and clinicians will need to follow the REMS program and the drug’s prescribing requirements. The source report says the label warns against use in people with heart failure and lists concurrent use with certain CYP2C19 or CYP3A4 medicines as contraindicated. Families should discuss a child’s existing conditions and medications with the treating cardiology team rather than treating the trial findings as individualized advice.
Further follow-up will be needed to clarify how the therapy performs in routine pediatric care and over longer periods. The FDA’s expanded indication is now the immediate change; the reported evidence does not provide a date for additional results or establish what further studies or label updates may follow.
heart condition management devices for kids
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Which children are covered by the expanded approval?
The indication covers children with symptomatic obstructive HCM who weigh at least 30 kg, or about 66 pounds. A clinician must determine whether the medicine is appropriate for a particular patient.
What evidence supported the FDA decision?
The approval was based on the phase III SCOUT-HCM trial, which randomized 44 adolescents. Over 28 weeks, mavacamten reduced the Valsalva LVOT gradient by 48.0 mm Hg from baseline compared with placebo, as reported in the source article.
Does the trial show that mavacamten is risk-free for children?
No. The study reported no ejection-fraction readings below 50%, atrial fibrillation, symptomatic heart failure or deaths among participating adolescents, but it involved 44 patients and 28 weeks of follow-up. Mavacamten can cause heart failure through systolic dysfunction and is subject to a restricted REMS program.
Is another cardiac myosin inhibitor approved for children?
According to the report, aficamten (Myqorzo) remains indicated only for adults with symptomatic obstructive HCM.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
